Stocktoria
FATE THERAPEUTICS INC FATE
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2013-10-01
FATE THERAPEUTICS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.6M | $13.6M | $63.5M | $96.3M | $55.8M |
| R&D expense | $107.8M | $135.0M | $172.6M | $320.5M | $215.5M |
| Operating income | -$147.7M | -$210.3M | -$190.5M | -$308.4M | -$217.0M |
| Interest expense | — | — | — | — | $0 |
| Income tax | $2,000 | $0 | $0 | $0 | $0 |
| Net income | -$136.3M | -$186.3M | -$160.9M | -$281.7M | -$212.2M |
| EPS (diluted) | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 |
| Operating cash flow | -$106.1M | -$122.9M | -$132.3M | -$248.2M | -$162.9M |
| Free cash flow | -$112.0M | -$123.6M | -$138.4M | -$283.8M | -$213.6M |
| Cash & equivalents | $46.6M | $36.1M | $41.9M | $61.3M | $133.6M |
| Total assets | $318.9M | $440.7M | $506.2M | $705.6M | $921.5M |
| Shareholders' equity | $207.2M | $318.7M | $368.4M | $483.9M | $678.8M |
Source: SEC EDGAR filings · CIK 0001434316 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.